Intellia Therapeutics Inc. (NTLA) got some good news on Tuesday when the FDA decided to lift its clinical hold on the company's MAGNITUDE-2 Phase 3 trial. The study tests nexiguran ziclumeran (nex-z for short) in patients with hereditary transthyretin amyloidosis with polyneuropathy, or ATTRv-PN if you prefer the acronym.

For those unfamiliar, ATTRv-PN is one of those devastating rare diseases that doesn't get much attention outside specialist circles. It's a genetic condition where proteins called transthyretin misfold and accumulate in peripheral nerves, progressively destroying sensory and motor function. It's fatal, it's inherited, and treatment options have historically been limited.

What Changed to Get the Trial Moving Again

The breakthrough came after Intellia worked out specific protocol modifications with the FDA. The key addition? Beefed-up safety monitoring focused on liver lab tests. The company also decided to expand enrollment from around 50 patients to approximately 60, giving the trial a bit more statistical cushion.

Researchers will be watching two primary endpoints: changes in a modified neuropathy impairment score (basically how well patients' nerves are functioning) and changes in serum TTR levels (the protein causing all the trouble).

The Backstory on Why This Matters

Here's where things get interesting. Back in September 2025, Intellia released promising long-term data from an ongoing Phase 1 study of the same drug. Among 33 patients who got a one-time dose of 0.3 mg/kg or higher, the average serum TTR reduction hit 92% at the two-year mark. The corresponding mean absolute serum TTR level was 17.3 g/mL, showing deep and durable effects.

Those are the kind of numbers that get biotech investors excited. A single dose producing sustained protein reduction for years? That's the promise of gene editing right there.

But then came October 2025, when reality reminded everyone that experimental therapies come with risks. The FDA slammed clinical holds on both MAGNITUDE trials after a patient in the heart disease study (MAGNITUDE, as opposed to MAGNITUDE-2 for nerve disease) experienced Grade 4 liver transaminase elevations and increased total bilirubin. Translation: serious liver toxicity that triggered the trial's pre-specified safety pause criteria.

What Happens Next

While the nerve disease trial is back on track, the company's other MAGNITUDE Phase 3 trial for transthyretin amyloidosis with cardiomyopathy (ATTR-CM, the heart version of the disease) remains on hold. Intellia says it's still talking with the FDA about that one and will provide updates once they figure out the path forward.

What the Analysts Think

William Blair analyst Myles Minter maintained his Market Perform rating on Intellia, though he sounds cautiously optimistic. "We continue to believe in the efficacy of Intellia's platform, and 2026 will be a major year for the promising HAE program, but safety events from nex-z have been and will continue to be a stock overhang until further regulatory clarity is gained on resumption of MAGNITUDE and as investors gain comfort with new risk-mitigation strategies, in our view."

Fair assessment. The science looks good, but nobody wants to downplay liver safety signals in gene therapy trials. The field has enough cautionary tales already.

Price Action: NTLA stock jumped 9.53% to $15.28 on Tuesday following the announcement.